Search

A 48-year-old woman with hormone receptor-negative (HR-) HER2+ metastatic breast cancer (mBC) showed lack of efficacy during treatment with pertuzumab, trastuzumab, and docetaxel. After experiencing rapid disease recurrence with hepatic metastases, she switched to off-label trastuzumab-deruxtecan monotherapy, which resulted in partial regression of the target lesion. Her condition remained stable after 13 cycles of treatment. [Extracted from the article]

A 42-year-old woman developed visual loss and bilateral papilloedema while undergoing treatment for HER2 positive breast cancer with docetaxel, carboplatin, and trastuzumab/pertuzumab. After four cycles of treatment, she experienced severe bilateral papilloedema, vision loss, headaches, and dizziness. The visual loss and papilloedema were attributed to the medication regimen, leading to its discontinuation, with the patient showing signs of recovery. Her treatment with trastuzumab/pertuzumab was continued while monitoring her progress. [Extracted from the article]

A 48-year-old woman experienced hand-foot syndrome (HFS) after receiving capecitabine and docetaxel for metastatic breast cancer, as well as squamous cell cancer (SCCa) of the skin following capecitabine treatment. Despite goserelin therapy for ovarian suppression, her breast cancer progressed rapidly. The woman underwent various treatments for HFS and skin cancer, including capecitabine adjustment and excision of nose lesions. Ultimately, she was diagnosed with SCCa of the skin due to capecitabine after years of treatment. [Extracted from the article]

A retrospective matched cohort study involving 14 adult women with early-stage HER2 positive breast cancer found that two patients developed cardiac dysfunction during treatment with trastuzumab. The patients had stage 1 and stage 3 HER2 positive breast cancer and received cyclical trastuzumab along with unspecified anthracyclines. One patient had trastuzumab interrupted, while the other continued treatment, both receiving unspecified heart failure therapies. [Extracted from the article]

A case report in the journal Reactions Weekly discusses a female patient who developed interstitial lung disease (ILD) after receiving treatment with trastuzumab-deruxtecan for HER2-positive metastatic breast cancer. The patient's therapy with trastuzumab-deruxtecan was discontinued, resulting in the complete resolution of ILD. Subsequently, the patient's treatment with trastuzumab-deruxtecan was reintroduced at reduced doses, leading to an improvement in her breast cancer. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA retrospective review of 36 patients was performed to investigates the efficacy of trastuzumab-deruxtecan between HER2+ and HER2-low breast cancers with active brain metastases (BM), et al. patient [age and sex not stated] was described, who exhibited lack of efficacy (progressive disease) during treatment with trastuzumab-deruxtecan for HER2+ breast cancer with active BM [route and dosage not stated]. [Extracted from the article]

A 61-year-old woman with recurrent HER2+ breast cancer developed pneumonitis while being treated with gemcitabine. She presented with altered mental status, weakness, and intermittent fever. Initial chest CT showed lung infiltrates consistent with acute respiratory distress syndrome. The woman required high-flow nasal cannula for oxygen support and was hospitalized for 7 weeks. Methylprednisolone was administered, and she clinically recovered and was discharged on home oxygen. [Extracted from the article]

A retrospective cohort study examined 36 female patients with HER-2 positive breast cancer who developed reduced left ventricular ejection fraction (LVEF) or heart failure during treatment with trastuzumab. Three case reports were described, all involving obese patients with a history of hypertension, hyperlipidemia, and left ventricular systolic dysfunction. In two cases, trastuzumab was discontinued and the patients received other medications to manage their condition. LVEF improved after discontinuation of trastuzumab in both cases, and one patient was able to restart and complete trastuzumab therapy. The outcomes for these patients were not stated. [Extracted from the article]

A study was conducted on 50 patients between August 2019 and February 2022, which included two women with HER2 positive breast cancer. Both women developed either low left ventricular ejection fraction (LVEF) or clinical cardiac dysfunction during their treatment with trastuzumab. Patient 1 experienced low LVEF, while Patient 2 developed clinical cardiac dysfunction. The specific doses, durations of treatment, and outcomes were not provided in the study. [Extracted from the article]

A 57-year-old woman with HER2 positive breast cancer and brain metastases experienced various toxicities and lack of efficacy during her treatment. She initially received capecitabine and pyrotinib, but developed diarrhea, nausea, and vomiting. Subsequent treatment with paclitaxel, trastuzumab, pertuzumab, and capecitabine also showed lack of efficacy. The woman underwent whole brain radiation therapy and started receiving anlotinib, pyrotinib, and letrozole, which resulted in successful tumor control. [Extracted from the article]

A 38-year-old woman with no medical history presented with symptoms of fatigue, pain, and other neurological issues. She was diagnosed with leptomeningeal carcinomatosis (LMC) and metastatic breast carcinoma. The woman underwent treatment with methotrexate, but after four weeks of therapy, it was discontinued due to lack of efficacy. She continued treatment with olaparib, but her condition worsened and she eventually passed away. [Extracted from the article]

A 65-year-old woman with metastatic HER2 positive breast cancer developed cardiomyopathy while receiving treatment with pertuzumab, trastuzumab, and docetaxel. She had previously experienced anthracycline-associated cardiomyopathy and was receiving medication for it. After receiving two cycles of the new treatment, her heart failure symptoms worsened significantly, and her left ventricular ejection fraction decreased. She received supportive care and her symptoms improved, but she later died from septic shock caused by bile duct obstruction. [Extracted from the article]

In a retrospective study of 39 women with metastatic breast cancer, a case was described of a woman who developed interstitial lung disease as a result of treatment with trastuzumab-deruxtecan. The woman also experienced a lack of efficacy with the treatment and ultimately died from disease progression. This case highlights the potential for drug toxicity and lack of effectiveness with trastuzumab-deruxtecan in the treatment of HER2+ metastatic breast cancer. [Extracted from the article]

A retrospective study examined 49 patients with HER2-positive breast cancer who received pyrotinib-neoadjuvant therapy. Four patients experienced grade 3 toxicities, including leukopenia, hypomagnesemia, elevated transaminase, and neutropenia. These toxicities were attributed to the use of pyrotinib. The study did not provide information on the patients' ages, sexes, treatment details, or outcomes. [Extracted from the article]

In a retrospective study of 456 patients with HER2-positive metastatic breast cancer, one female patient developed intolerance of diarrhea during treatment with pyrotinib. The patient received oral pyrotinib at a standard dose of 400 mg/day but had to discontinue the treatment due to the intolerance. Her cancer progressed after 2 months, but the pyrotinib-based regimen was restarted and she had a progression-free survival of 11.50 months. [Extracted from the article]

A 54-year-old woman with metastatic hormone receptor positive HER2 negative breast cancer developed cystoid macular oedema during treatment with paclitaxel. She experienced profound bilateral vision loss during the seventh cycle of paclitaxel. After discontinuing paclitaxel, her vision improved after 4 weeks of discontinuation and she received dorzolamide, which resulted in a rapid resolution of the cystoid macular oedema. [Extracted from the article]

This article discusses two case reports of women in their 50s and 60s who developed drug-induced interstitial lung disease (DILD) during treatment for breast cancer. The first woman experienced a fever and chest CT showed ground-glass opacities. She was diagnosed with chemotherapy-induced DILD and treated with steroids, which resolved her symptoms. The second woman had a lack of efficacy with certain chemotherapy drugs and developed mild ground-glass opacities in her lungs. She was diagnosed with chemotherapy-induced DILD and her treatment was changed, resulting in resolution of her lung damage. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a retrospective single-arm, observational study involving 144 women conducted from 28 October 2019 to 13 October 2021, one adult woman [exact age not stated] was described, who developed neutropenia during treatment with IV trastuzumab [Kanjinti] for HER2+ breast cancer [dosage, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

A 40-year-old woman with Bechet's disease and asthma developed various toxicities during treatment for HER2 positive breast cancer. She experienced stomatitis, fatigue, decreased appetite, headache, fever, recurrent oral aphthae, facial erythema, dysarthria, disturbance of consciousness, and left hemiplegia. She was hospitalized and treated with steroid pulse therapy, which improved her symptoms. After discharge, she underwent surgery and continued therapy without recurrence of breast cancer or Bechet's disease. [Extracted from the article]

In a retrospective study involving 81 patients with metastatic HER2-positive breast cancer, two patients experienced hypoesthesia and grade 3 neutropenia after receiving off-label treatment with disitamab-vedotin. The patients had a history of metastatic HER2-positive breast cancer and received varying dosages of disitamab-vedotin. The development of hypoesthesia and grade 3 neutropenia was attributed to the use of disitamab-vedotin. It is important to note that this information is based on a case report that has been previously published. [Extracted from the article]

A 40-year-old woman with HER2 positive breast cancer experienced mild to moderate local site reactions while being treated with montanide-ISA-51. She also showed lack of efficacy during treatment with carboplatin, docetaxel, and trastuzumab. The woman underwent personalized peptide immunization using BITAP immunization peptide pools over five years, which stabilized her condition. However, she did experience mild to moderate local site reactions, which were the most common side effects of montanide-ISA-51. [Extracted from the article]

A multicenter study observed four female patients with HER-2-positive breast cancer who experienced adverse effects while being treated with trastuzumab and pertuzumab. The patients developed decreased left ventricular ejection fraction, drug-induced liver injury, or diarrhea. The patients received either reference trastuzumab or a biosimilar version, and the adverse effects varied depending on the treatment. Treatment was temporarily stopped for the patient who developed drug-induced liver injury. [Extracted from the article]

A 42-year-old woman with HER2 positive breast cancer developed diarrhea while being treated with pyrotinib. She also experienced treatment failure while receiving trastuzumab. The woman had initially undergone surgery and received chemotherapy and trastuzumab. After the failure of trastuzumab, she was treated with pyrotinib and experienced diarrhea again. The development of diarrhea was attributed to pyrotinib. She continued treatment with pyrotinib and underwent brain radiotherapy. [Extracted from the article]

A 42-year-old woman with HER2 positive breast cancer developed diarrhea while being treated with pyrotinib. She also experienced treatment failure while receiving trastuzumab. The woman had initially undergone surgery and received chemotherapy and trastuzumab. After the failure of trastuzumab, she was treated with pyrotinib and experienced diarrhea again. The development of diarrhea was attributed to pyrotinib. She continued treatment with pyrotinib and underwent brain radiotherapy. [Extracted from the article]

In a real-world study of 179 patients with HER-2 positive breast cancer, two patients experienced adverse reactions while being treated with carboplatin. One patient developed severe diarrhea, while the other had high creatinine levels. Both patients had a medical history of HER-2 positive breast cancer and were receiving carboplatin in combination with other medications. The dose of carboplatin was initially reduced for both patients and eventually discontinued. [Extracted from the article]

A 51-year-old woman with stage II HER2 positive breast cancer experienced lack of efficacy during treatment for clostridium difficile colitis. She had previously undergone a bilateral mastectomy and received adjuvant chemotherapy. After being diagnosed with clostridium difficile colitis, she was treated with metronidazole, oral vancomycin, and IV cefipime. Despite treatment, her condition worsened, and she underwent a diverting ileostomy and later a total colectomy. Unfortunately, she developed liver and bone metastases and passed away a year later. [Extracted from the article]

A 36-year-old woman developed sarcoid granulomatous lymphadenitis while undergoing treatment with trastuzumab for breast cancer. The woman had different types of breast cancer in each breast and was receiving trastuzumab along with other medications. A lymph node biopsy revealed sarcoid granulomata, but no signs of malignancy or metastases were found. The condition was determined to be related to the use of trastuzumab. [Extracted from the article]

In a study evaluating the safety and immunogenicity of trastuzumab in female patients with HER2-positive advanced breast cancer, a woman developed a decline in left ventricular ejection fraction during treatment with trastuzumab. The woman received trastuzumab at doses of 8 mg/kg and 6 mg/kg for subsequent cycles every 3 weeks. However, her left ventricular ejection fraction decreased by at least 10% as a result of the trastuzumab treatment. The duration of treatment and outcome were not specified. [Extracted from the article]

A real-world study examined the efficacy of trastuzumab-deruxtecan in 29 women with advanced breast cancer. Two women in the study experienced a lack of efficacy with the treatment. Patient 1 had progressive disease while on trastuzumab-deruxtecan, and Patient 2 experienced disease progression that ultimately resulted in death. The study provides insights into the effectiveness of trastuzumab-deruxtecan for advanced breast cancer. [Extracted from the article]

A retrospective study of 52 patients treated with trastuzumab-deruxtecan for metastatic HER2 positive breast cancer found that two patients developed fatigue or interstitial lung disease during treatment. One patient received trastuzumab-deruxtecan with radiation therapy, while the other received it without radiation therapy. Both patients experienced adverse effects, including grade 3 nausea and grade 2 interstitial lung disease. Trastuzumab-deruxtecan was discontinued in one patient. [Extracted from the article]

A 63-year-old woman with hormone receptor positive HER2 negative breast cancer experienced lack of efficacy while being treated with letrozole. She also developed a duodenal ulcer and crystal-duodenal mucosal injury during treatment with ribociclib. The woman was admitted to the hospital with symptoms of epigastric pain, nausea, vomiting, and fever. Biopsy results confirmed the diagnosis of ribociclib-associated duodenal ulcer and crystal-duodenal mucosal injury. After discontinuing the medications and receiving treatment, the woman's symptoms improved and she was discharged without complications. However, when she restarted ribociclib, she experienced epigastric pain again, leading to a change in medication. Follow-up endoscopy showed complete resolution of the crystal-duodenal mucosal injury and duodenal ulcer. [Extracted from the article]

In a retrospective cohort study of patients with HER2-positive breast cancer, several individuals developed cardiotoxicity in the form of left ventricular dysfunction while being treated with trastuzumab or epirubicin. The patients experienced reduced left ventricular ejection fraction and impaired global longitudinal strain, and some also developed heart failure. Trastuzumab was continued in some cases, but three patients eventually had to discontinue the treatment due to cardiac dose-limiting toxicity. The cardiotoxicity persisted in seven patients even after completion or discontinuation of trastuzumab. The study concluded that the cardiotoxicity was related to trastuzumab and/or epirubicin. [Extracted from the article]

A retrospective analysis of 2583 female patients with HER2+ breast cancer treated with pertuzumab and trastuzumab revealed that three patients developed pruritus during treatment. One patient experienced high-grade pruritus, while the other two had milder symptoms. One patient discontinued the entire treatment regimen, while another patient discontinued only pertuzumab. Both patients switched to different regimens but did not experience improvement in pruritus after intervention by oncology or dermatology. The duration of treatment to reaction onsets and all outcomes were not stated. [Extracted from the article]

A case study involving 11 women with recurrent breast cancer found that two of them developed grade 3 neutropenia or interstitial lung disease while being treated with trastuzumab-deruxtecan, a medication for HER2-positive breast cancer. One woman experienced neutropenia but her dose was reduced after she recovered. The other woman developed interstitial lung disease and was hospitalized, but later discharged after treatment with steroids. [Extracted from the article]

A study examined the cardiotoxicity of trastuzumab, a drug used to treat HER2 positive breast cancer. The study included 117 patients and found that three women experienced cardiac issues during treatment. One woman developed asymptomatic cardiotoxicity, another developed symptomatic cardiotoxicity, and a third woman experienced sudden cardiac death. The study did not provide information on the final outcomes of these adverse reactions or the duration of treatment before the onset of these reactions. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 73-year-old woman exhibited lack of efficacy during treatment with cyclophosphamide, docetaxel, epirubicin, pertuzumab and trastuzumab for metaplastic breast cancer [routes and dosages not stated]. [Extracted from the article]

A retrospective study involving 81 patients with HER2-positive breast cancer found that one patient developed febrile neutropenia while being treated with docetaxel, pertuzumab, and trastuzumab. The study did not provide specific details about the patient's age, sex, treatment regimen, or outcome. [Extracted from the article]

Later, the patient started receiving 12 doses of concurrent weekly paclitaxel 80 mg/m SP 2 sp and trastuzumab 4 mg/kg loading followed by trastuzumab 2 mg/kg (PT regimen), then followed by four cycles of doxorubicin 60 mg/m SP 2 sp and cyclophosphamide 600 mg/m SP 2 sp (AC regimen). Patient 2: A 42-year-old patient, who was diagnosed with HER2-positive breast cancer, started receiving four cycles of cyclophosphamide 500 mg/m SP 2 sp , doxorubicin 50 mg/m SP 2 sp and fluorouracil 500 mg/m SP 2 sp [5-FU; CAF regimen] and underwent surgery. Patient 5: A 62-year-old patient, who was diagnosed with HER2-positive breast cancer, started receiving four cycles of cyclophosphamide 500 mg/m SP 2 sp , doxorubicin 50 mg/m SP 2 sp and fluorouracil 500 mg/m SP 2 sp [5-FU; CAF regimen] and underwent surgery. [Extracted from the article]

Thyroid function test results further showed elevated TSH, decreased FT4 and free triiodothyronine (FT3), and elevated antibodies against thyroglobulin (anti-Tg). A thyroid function test in February, showed elevated thyroid-stimulating hormone (TSH) and decreased free thyroxine (FT4) levels. Later, the TSH normalised, while thyroid ultrasonography showed an increased thyroid gland, with lobulated contours, with the left lobe more prominent than the right and with a heterogeneous hypoechoic parenchyma, with multiple pseudonodular areas. [Extracted from the article]